FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - December 5, 2025 91 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Being Diagnosed With a Childhood Cancer As an Adult Led Me... May 18, 2023 Improving research with registered reports May 16, 2022 Are Cancer Patients Getting the Opioids They Need to Control Pain? September 16, 2020 Lawmaker Dad Raises Awareness For RSV, An Illness He’d Never Heard... November 20, 2019 Load more HOT NEWS Study Shows 4 Drugs Better Than 3 for Women with HER2-Positive... New on NCI’s Websites for April 2024 Immune cell count could determine whether chemotherapy is required in oropharyngeal... Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients...
